Rachel Humphrey insider trades: Pyxis Oncology (PYXS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Rachel reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | PYXS | ↓ Sell | 15,496 | $1.03 | $16K | Direct | Mar 25, 2026 (338d) |
| Mar 2, 2018 | CTMX | ↓ Sell | 16,160 | $30.00 | $485K | Direct | Mar 5, 2018 (3d) |
| Feb 28, 2018 | CTMX | ↓ Sell | 23,840 | $30.00 | $715K | Direct | Mar 2, 2018 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PYXS insiders
Open-market trades in the last 12 months
About Rachel Humphrey's insider trades
Rachel Humphrey is an insider at Pyxis Oncology (PYXS). Since Feb 28, 2018, Rachel has reported no open-market purchases and 3 sales worth $1.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PYXS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.